Furthermore, a meta-analysis of eight studies comprising 2071 patients suggested that a high expression of MSH2 was associated with a poor prognosis for prostate cancer (HR = 1.38, 95% CI = 1.12–1.69, p = 0.002) (Figure 6). Here, MSH2 is linked to Familial prostate cancer.